Navigation Links
New Improved Dosing Approved for Pennsaid
Date:6/3/2008

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, and Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved a new dosing regimen for Pennsaid(R) (topical diclofenac). Paladin sells and markets Pennsaid in Canada, having acquired exclusive Canadian Pennsaid rights from Nuvo in August 2005.

The new dosing regimen of Pennsaid(R) will be 50 drops per knee, 3 times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, 4 times a day. Pennsaid(R) is now the only topical NSAID approved in Canada with this new improved dosing regimen. Pennsaid had Canadian sales of $10.6 million last year and has been sold in Canada since May 2003.

"Pennsaid(R) is a proven effective treatment for Osteoarthritis of the knee," said Dr. Philip Baer, a Rheumatologist practicing in Ontario. "The newly approved dosing regimen of 50 drops TID (three-times-per-day) will make it easier for patients to use Pennsaid(R) to manage their pain, as compared to applying 40 drops QID (four-times-per-day). TID dosing can improve patient compliance, which is one of the most important factors in ensuring effective pain relief."

"The new improved dosing regimen of Pennsaid(R) is a significant clinical advantage," said Henrich Guntermann, Nuvo's President and CEO. "We are eager to replicate Pennsaid's Canadian success in the U.S. market and continue to work diligently on obtaining U.S. FDA approval."

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Paladin web site at http://www.paladinlabs.com.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego California. For more information, please visit http://www.nuvoresearch.com.

This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Companies' annual information forms filed with the securities commissions in each of the provinces of Canada. The Companies referred to herein undertake no obligation to revise forward-looking statements in light of future events.


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
2. MedQuist Re-launches New, Improved Web Site
3. Gene chip data improved therapy in some patients with incurable cancer
4. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
5. Innovator Award to Berkeley Labs Joe Gray for improved breast cancer screening
6. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
7. Oridion Introduces New Smart Capnography System for Improved Patient Safety
8. Nursing Home Workers From Across the Nation to Rally in for Improved Nursing Home Care
9. Services for patients with BPD need to be improved say psychiatric nurses
10. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
11. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... LaserShip, a regional parcel carrier that services the eastern U.S., ... last Friday in order to aid in the Flint water crisis. In 2014, LaserShip ... located in Clio, only 15 miles away from Flint. , “We have deep roots ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... ... , ... 10 Best Water is excited to announce a new ... that topped the list as a result of their commitment to offering clients creative, ... Tibet 5100, a top notch water company that specializes in providing the public with ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... measure change in their patients. Research shows that the Goal Attainment Scale (GAS) ... therapists overcome this challenge and learn more about the Goal Attainment Scale, Education ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
(Date:2/11/2016)... CITY, Calif. , Feb. 11, 2016  AcelRx ... a podium presentation will be made at the 38th ... and Wound Care Symposium, which is being held ... This international conference covers the latest advancements in wound ... by the American Burn Association, Australian-New Zealand Burns Association, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology: